Sanofi Drug Shows Long-Term Benefit
Blueprint Medicines, a Sanofi company, announced positive four-year data for its drug AYVAKIT in treating indolent systemic mastocytosis. A real-world study showed the drug provided sustained benefits and long-term safety, highlighting improvements across the rare disease's symptoms. The data was presented at the 2026 AAAAI Annual Meeting.
Indolent systemic mastocytosis is a rare blood disorder driven by the KIT D816V genetic mutation in about 95% of cases. This mutation leads to an overproduction of mast cells, causing severe and unpredictable symptoms like rashes, gastrointestinal issues, brain fog, and bone pain. AYVAKIT (avapritinib) is a kinase inhibitor specifically designed to target and potently inhibit the KIT D816V mutation. By blocking this primary driver, the drug reduces the abnormal accumulation and activation of mast cells that cause the disease's debilitating symptoms. The U.S. Food and Drug Administration approved AYVAKIT for indolent systemic mastocytosis on May 22, 2023, making it the first and only approved therapy for this condition. This followed an earlier approval in June 2021 for advanced forms of systemic mastocytosis. The approval was based on the PIONEER clinical trial, the largest study ever conducted for this disease. In that pivotal study, AYVAKIT demonstrated significant improvements in overall symptoms and reduced mast cell burden compared to a placebo. This marked a significant shift in treatment, moving beyond merely supportive care—which only addresses symptoms—to a disease-modifying therapy that targets the underlying cause. While showing long-term benefits, the most common adverse reactions reported in patients with indolent systemic mastocytosis include eye edema, dizziness, peripheral edema, and flushing.
